Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Zabrze – page 64

1 174 clinical trials in Zabrze, Poland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Zabrze at a glance
1 174
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 174 trials in Zabrze

Open in trial search

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Nonbiologic Standard of Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Symptom Changes in Adults with Chronic Rhinosinusitis with Nasal Polyps Using Tezepelumab

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Not recruiting

Study on Guselkumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Switching from Daily Basal Insulin to Weekly Insulin Icodec Compared to Daily Insulin Glargine in Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Multiple sclerosis

Not recruiting

Study Comparing Subcutaneous and Intravenous Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Obesity+1

Not recruiting

Evaluation of Tirzepatide Versus Placebo in Adolescents with Obesity or Overweight and Weight-Related Comorbidities: A Randomized, Double-Blind Clinical Trial

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Multiple sclerosis

Not recruiting

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Systemic sclerosis pulmonary

Not recruiting

Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Obesity

Not recruiting

Comparing the efficacy and safety of KAI-9531 and semaglutide in people living with obesity who do not have diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531
  • Sponsor:Kailera Therapeutics Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Zabrze

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking trials focusing on heart failure treatment and prevention, including studies of novel drug combinations like baxdrostat/dapagliflozin and sacubitril/valsartan. Research encompasses various cardiac conditions, from post-myocardial infarction care to atrial fibrillation management.

  • Heart Failure Prevention
  • Cardiomyopathy Treatment
  • Post-Transplant Care

Multiple studies are examining innovative approaches to cardiac health management and prevention strategies.

02 Neurological Disorders

Advanced clinical research in multiple sclerosis treatments, testing new therapies like frexalimab and ublituximab. Studies also include innovative approaches to treating Alzheimer's disease and chronic inflammatory demyelinating polyneuropathy.

  • Multiple Sclerosis Management
  • Dementia Treatment
  • Neuropathy Research

Trials focus on improving patient outcomes and developing more effective treatment protocols.

03 Metabolic Conditions

Comprehensive studies addressing obesity management and diabetes control, particularly in adolescent populations. Research includes evaluation of new treatments like tirzepatide and innovative insulin therapies.

  • Weight Management
  • Type 2 Diabetes
  • Growth Disorders

Research aims to develop more effective treatments for metabolic disorders across different age groups.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.